Christakis Constantinides1, Pooja Basnett2, Barbara Lukasiewicz2, Ricardo Carnicer1, Edyta Swider3, Qasim A Majid4, Mangala Srinivas3, Carolyn A Carr5, Ipsita Roy2. 1. Radcliffe Department of Medicine, Wellcome Trust Centre for Human Genetics, Department of Cardiovascular Medicine , University of Oxford , Roosevelt Drive, Old Road Campus , Headington, Oxford OX3 7BN , U.K. 2. Applied Biotechnology Research Group, Faculty of Science and Technology , University of Westminster , 115 New Cavendish Street , London W1W 6UW , U.K. 3. Radboud University Medical Center (Radboud UMC), Department of Tumor Immunology , Radboud Institute for Molecular Life Sciences (RIMLS) , 278, P.O. Box 9101, 6500HB Nijmegen , The Netherlands. 4. Department of Myocardial Function , National Heart and Lung Institute, Imperial College London , London W12 0NN , U.K. 5. Department of Physiology, Anatomy, and Genetics , University of Oxford , South Parks Road , Oxford OX1 3PT , U.K.
Abstract
Medium-chain length polyhydroxyalkanoates (MCL-PHAs) have demonstrated exceptional properties for cardiac tissue engineering (CTE) applications. Despite prior work on MCL-PHA/polycaprolactone (PCL) blends, optimal scaffold production and use as an alternative delivery route for controlled release of seeded cardiac progenitor cells (CPCs) in CTE applications in vivo has been lacking. We present herein applicability of MCL-PHA/PCL (95/5 wt %) blends fabricated as thin films with an improved performance compared to the neat MCL-PHA. Polymer characterization confirmed the chemical structure and composition of the synthesized scaffolds, while thermal, wettability, and mechanical properties were also investigated and compared in neat and porous counterparts. In vitro cytocompatibility studies were performed using perfluorocrown-ether-nanoparticle-labeled murine CPCs and studied using confocal microscopy and 19F magnetic resonance spectroscopy and magnetic resonance imaging (MRI). Seeded scaffolds were implanted and studied in the postmortem murine heart in situ and in two additional C57BL/6 mice in vivo (using single-layered and double-layered scaffolds) and imaged immediately after and at 7 days postimplantation. Superior MCL-PHA/PCL scaffold performance has been demonstrated compared to MCL-PHA through experimental comparisons of (a) morphological data using scanning electron microscopy and (b) contact angle measurements attesting to improved CPC adhesion, (c) in vitro confocal microscopy showing increased SC proliferative capacity, and (d) mechanical testing that elicited good overall responses. In vitro MRI results justify the increased seeding density, increased in vitro MRI signal, and improved MRI visibility in vivo, in the double-layered compared to the single-layered scaffolds. Histological evaluations [bright-field, cytoplasmic (Atto647) and nuclear (4',6-diamidino-2-phenylindole) stains] performed in conjunction with confocal microscopy imaging attest to CPC binding within the scaffold, subsequent release and migration to the neighboring myocardium, and increased retention in the murine myocardium in the case of the double-layered scaffold. Thus, MCL-PHA/PCL blends possess tremendous potential for controlled delivery of CPCs and for maximizing possible regeneration in myocardial infarction.
Medium-chain length polyhydroxyalkanoates (MCL-PHAs) have demonstrated exceptional properties for cardiac tissue engineering (CTE) applications. Despite prior work on MCL-PHA/polycaprolactone (PCL) blends, optimal scaffold production and use as an alternative delivery route for controlled release of seeded cardiac progenitor cells (CPCs) in CTE applications in vivo has been lacking. We present herein applicability of MCL-PHA/PCL (95/5 wt %) blends fabricated as thin films with an improved performance compared to the neat MCL-PHA. Polymer characterization confirmed the chemical structure and composition of the synthesized scaffolds, while thermal, wettability, and mechanical properties were also investigated and compared in neat and porous counterparts. In vitro cytocompatibility studies were performed using perfluorocrown-ether-nanoparticle-labeled murine CPCs and studied using confocal microscopy and 19F magnetic resonance spectroscopy and magnetic resonance imaging (MRI). Seeded scaffolds were implanted and studied in the postmortem murine heart in situ and in two additional C57BL/6 mice in vivo (using single-layered and double-layered scaffolds) and imaged immediately after and at 7 days postimplantation. Superior MCL-PHA/PCL scaffold performance has been demonstrated compared to MCL-PHA through experimental comparisons of (a) morphological data using scanning electron microscopy and (b) contact angle measurements attesting to improved CPC adhesion, (c) in vitro confocal microscopy showing increased SC proliferative capacity, and (d) mechanical testing that elicited good overall responses. In vitro MRI results justify the increased seeding density, increased in vitro MRI signal, and improved MRI visibility in vivo, in the double-layered compared to the single-layered scaffolds. Histological evaluations [bright-field, cytoplasmic (Atto647) and nuclear (4',6-diamidino-2-phenylindole) stains] performed in conjunction with confocal microscopy imaging attest to CPC binding within the scaffold, subsequent release and migration to the neighboring myocardium, and increased retention in the murine myocardium in the case of the double-layered scaffold. Thus, MCL-PHA/PCL blends possess tremendous potential for controlled delivery of CPCs and for maximizing possible regeneration in myocardial infarction.
Stem cell (SC) delivery has been proposed and applied as a novel
and promising therapeutic approach for cardiac diseases.[1−3] However, to-this-date, there is continued speculation over its efficacy,
given the disparity of published preclinical and clinical results,[4,5] despite scientific evidence for the existence of paracrine effects
associated with beneficial functional improvements in the infarcted
myocardium.[6] Therefore, controlled SC administration
and release still presents tremendous challenges toward a therapeutically
successful cell engineering approach.Polymer scaffolds have
been introduced as a novel, biomimetic approach for administration
and controlled release of viable SCs to the diseased myocardium,[7] ultimately aiming to replace scar tissue with
engrafted healthy cells with pluripotent/multipotent capacity.Historically, the earliest attempts for tissue regeneration date
to the early 1970s with the use of grafts over the injured myocardium.[8] The first efforts to deliver cells within scaffolds
were pioneered by Souren et al.,[9] while
more recent attempts target the use of inducible pluripotent SCs.[10]To this-date, collective efforts in cardiac
tissue engineering (CTE) have employed natural and synthetic materials
and have been tested with a multitude of SC types[8,11] in
different hosts, including the mouse, rat, rabbit, pig, sheep, dog,
and human.[8] The scaffold substrates have
been synthesized using materials, such as collagen, fibrin, chitosan,
alginate,[12] hyaluronic acid, gelatin, matrigel,
decellularized extracellular matrix,[13,14] and hydrogels.[15,16]In recent years, the scientific preference has shifted toward
scaffolds synthesized using natural materials given their biodegradable
and biocompatible properties, emulating closely the myocardial microenvironment.
Specifically, medium-chain length polyhydroxyalkanoates (MCL-PHA)
have generated great interest over recent years as functional materials
in cardiac tissue engineering, with biodegradable, biocompatible,
and synthetically tunable physical properties,[17] including flexibility, crystallinity, melting point, and
glass transition temperatures.[18] Induced
porosity and functionalization of these materials with growth factors
and active peptide molecules (without and with electrospun blend fibers)
has also led to the fabrication of cardiac patches with excellent
morphological properties and upregulation of cues from the innate
matrix structure, thereby promoting enhanced SC (endothelial, inducible
pluripotent) adhesion and proliferation.[17,19] Furthermore, MCL-PHA patches have been shown to exhibit similar
mechanical properties to myocardial muscle, with a flexibility and
rigidity that can sustain the cyclic strain patterns developed during
the contractile–relaxation phases of the cardiac cycle, over
prolonged periods that span multiple weeks.[19] In addition, these polymers exhibit degradation by surface erosion,
leading to the maintenance of the scaffold’s structure for
a longer period of time, and hence provide better support functionality.
Overall, MCL-PHAs are versatile, biocompatible, biodegradable, sustainable,
display thermoplastic and elastomeric properties, and have predictable
mechanical and physical characteristics.[20] They can be mass-produced using controlled fermentations,[21] and their biodegradation products are much less
acidic (with hydroxyalkanoic acids as the main degradation byproducts)
as compared to those of poly(l-lactic acid) (PLLA) and PLGA,
thereby leading to less severe inflammatory responses. However, MCL-PHAs
are associated with high production costs.In comparison to
MCL-PHAs, synthetic materials, such as PLLA,[22] are readily available and are associated with well-established processing
conditions; however, PLLA films are much stiffer than MCL-PHAs and
exhibit poorer degradation responses (bulk erosion),[19] ultimately causing plastic deformation and failure during
long-term exposure to cyclic strain.[17] Additionally,
PLLA degradation products are acidic in nature, which ultimately leads
to inflammation and other undesirable reactions.[23]Polycaprolactone (PCL)[24] is an elastomeric synthetic polymer that is adaptable, versatile,
produced in large scale, is associated with precise synthetic control
using easily accessible materials and prolonged degradation time,[25,26] has good miscibility with various polymers, and possesses good and
predictable mechanical and physical characteristics, often used in
load-bearing tissues to enhance stiffness,[25] although associated with very low glass transition and melting temperatures.[27]Despite these advantages, PCL is a nonsustainable
polymer, and its production methods include solvent- and catalyst-based
synthesis. In addition, PCL does not exhibit structural variability
and, consequently, the resulting range of material properties exhibited
by MCL-PHAs.In view of these facts, polymeric MCL-PHA/PCL blends
were used in this work to overcome the limitations of each of these
polymer families, allowing the alteration of the mechanical properties
of PCL and thereby enhancing the processability of the combined polymer
product. Despite the existence of prior published work on MCL-PHA/PCL
blends,[25,26,28−32] the reported compositions, aging, testing, and targeted applications
have been distinctly different from this work, and they have not been
previously used for CTE applications in either unseeded or seeded
forms.Correspondingly, in this effort, we aimed to synthesize
MCL-PHA/PCL blend scaffold compositions seeded for the first time
with cardiac progenitor cells (CPCs) enhancing the elicited benefits
by capitalizing on the advantages of each material class.Critical
to the successful administration and controlled release of SCs by
the scaffold is our ability to monitor them noninvasively, particularly
in a temporal manner.[33] Even though bioluminescence
imaging using reporter genes (such as luciferase) has allowed real-time,
in vivo monitoring of viable SCs implanted on scaffolds,[34] the spatial localization of the scaffold and
its degradability pattern are not easily discernible.In this
work, we propose the use of novel, functional biodegradable, biocompatible
natural/synthetic polymer blend scaffolds (composed of MCL-PHA and
PCL) to (a) benefit from the material properties of natural and synthetic
polymers, (b) achieve controlled delivery of homologous CPCs—previously
shown to elicit beneficial functional effects (in the chronic phase)
following acute, reperfused myocardial infarction (MI), in preclinical[6] and clinical studies[4]—thereby aiming to increase retention of delivered cells to
the murine myocardium, (c) extend the temporal window over which the
release of labeled CPCs is achieved compared to traditional direct
injection techniques,[35] and (d) use 19F magnetic resonance imaging (MRI)/magnetic resonance spectroscopy
(MRS) to noninvasively detect and monitor the cells temporally.The choice of the blend material underlies one of the important novelties
of this work, given the increased ability of structural control in
terms of its elastomeric nature and mechanical properties, the increased
glass transition temperatures compared to neat PCL, and its potential
to integrate with the myocardial network and be conjugated with bioactive
molecules, such as vascular endothelial growth factor (VEGF) and Arg-Gly-Asp
(RGD)/Tyr-Lle-Gly-Ser-Arg (YIGSR) peptides to further increase cellular
attachment, viability, and proliferation.[17,19] Another novelty relates to the visualization and monitoring of the
repair process using 19F MRI. The latter aim is pursued
in a physiological model, despite the challenge of the low seeding
density, as this is governed by the small size of the murine heart,
stringent anatomical limitations regarding the scaffold’s placement,
the endogenous hypoxic conditions, and the temporally dependent migration/dispersion
of cells within the murine epicardium/mesocardium.
Experimental Procedures
Production
of Poly-3-hydroxyalkanoates (PHAs)
Production
of MCL-PHAs
MCL-PHAs were produced by Pseudomonas
mendocina CH50 using glucose as the sole carbon source
under nitrogen limiting conditions.[36] Batch
fermentation was carried out in a 15 L bioreactor with an operating
fermenter volume of 10 L. MCL-PHA production was completed in three
stages:
Preparation of Inoculum
A single
colony of P. mendocina CH50 was used
to inoculate sterile nutrient broth. The broth was incubated at 30
°C, at 200 rpm for 16 h.
Preparation
of Second Stage Seed Culture
The inoculum prepared at the
first stage was used to inoculate a second stage mineral salt medium
(MSM) with glucose as the carbon source. It was incubated at 30 °C,
at 200 rpm for 24 h.
Preparation and Inoculation
of Production Stage Media
Prior to the inoculation of the
production media, the fermenter was sterilized at 121 °C for
30 min. The sterile mixture of MSM, glucose, magnesium sulfate, and
trace element solution was aseptically added to the fermenter. The
second stage seed culture was used to inoculate the production media.
The culture was grown for a period of 48 h at 30 °C and at 200
rpm.
Extraction of MCL-PHA
The biomass was recovered by centrifuging the fermented cultures
at a speed of 4600 rpm for approximately 45 min. The obtained biomass
was lyophilized prior to extraction. MCL-PHA was extracted using the
two-stage soxhlet extraction method. The powdered biomass was refluxed
in methanol for 24 h to remove the impurities. The polymer was then
extracted in chloroform for another 24 h. The solution was concentrated
using a rotary vacuum evaporator and the polymer was precipitated
using ice-cold methanol (1:10 polymer solution to ice-cold methanol).
Polymer Characterization
Chemical Characterization
Fourier
Transform Infrared Spectroscopy (FTIR)
FTIR analysis was
also conducted using a Perkin-Elmer Spectrum Two spectrometer, as
described earlier.[17]
Nuclear Magnetic Resonance (NMR)
NMR was conducted
on a 16.4 T (700 MHz), high-field spectrometer (Bruker, Billerica,
MA, USA) at University College, London. Samples were prepared in accordance
to standard methodological procedures, as reported earlier.[36,37]
Thermal Characterization
Thermal
properties of the polymer, such as the melting temperature (Tm) and the glass transition temperature (Tg), were determined using a differential scanning
calorimetry (DSC) system (model DSC 214, Polyma, Netzsch, Germany),
equipped with an intracooler IC70 cooling system. A polymer sample
(5 mg) was heated from −70 to 170 °C at a heating rate
of 10 °C per minute over two successive heating–cooling
cycles. The analysis was completed at the end of two heating cycles.
DSC thermograms were analyzed using the Proteus 7.0 software.
Molecular Weight Analysis
The number average molecular
weight, (Mn), and the weight average molecular
weight, (Mw), of the polymer were determined
using gel permeation chromatography (GPC, model 1260 Infinity GPC,
Agilent Technologies). The polymer solution (2 mg/mL) was introduced
into the GPC system at a flow rate of 1 mL/min. The system was equipped
with a 5 μm PLgel MIXED-C (300 × 7.5 mm) column calibrated
using narrow molecular weight polystyrene standards from 162 Da to
15 kDa. The eluted polymer was detected with a refractive index detector.
The data were analyzed using the Agilent GPC/SEC software.
Scaffold Synthesis and Characterization
MCL-PHA films were prepared using the solvent casting method.[38] Nonporous MCL-PHA films were prepared by dissolving
the polymer (0.5 g) in chloroform (10 mL). The MCL-PHA solution was
poured into a glass Petri dish and was allowed to dry in a closed
chamber. Polymer blends were prepared by dissolving 0.5 g of polymer
with 0.26 g of PCL (Sigma-Aldrich, UK).To prepare porous films,
1.7 g of sodium chloride with particular sizes (75, 100 μm)
was used as the porogen. These were added into the polymer solution,
mixed, and then poured into glass Petri dishes. Upon drying, these
films were immersed in water to allow sodium chloride to leach out
of the films.[39,40] These films were dried in a closed
chamber.The ultimate choice of the 95/5 wt % MCL-PHA/PCL blend
composition was attributed to the outcomes elicited from empirical
optimization tests (at different blend compositions and porosities)
and was based on a previous study on PHA-based blends in relation
to nerve tissue engineering using 95/5 and 75/25 wt % MCL-PHA/PCL
blends.[41]
Mechanical
Characterization
Mechanical properties of the porous and
nonporous films were tested using an Instron tensile testing system
(Instron, model 5942 Testing Systems, Buckinghamshire, UK). This analysis
was carried out on solvent cast film strips of specified widths and
lengths (n = 3, >23 mm in length and 5 mm in width).
Tensile strength, elongation at break (%), and Young’s modulus
values were determined from the stress–strain curves using
the Instron’s analysis package (BlueHill 3) or via offline
analysis.
Morphological Properties
Surface properties of the porous and the nonporous films were studied
using a FEI XL30 FEG scanning electron microscope (FEI, Eindhoven,
Netherlands). MCL-PHA film samples were mounted on conducting aluminum
stubs and were coated with gold–platinum using an Polaron E5000
Sputter Coater (Quorum Technologies Ltd, Newhaven, East Sussex, UK)
for approximately 2 min before they were imaged using the SEM. The
images were acquired using an acceleration voltage of 10 kV at a 10
cm working distance at the Eastman Dental Institute, University College,
London.
Hydrophobicity-Contact Angle Measurements
Contact angle (θ) measurements were performed using a KSV
Cam 200 optical contact angle measurement system (KSV Instruments
Ltd.) on both porous as well as nonporous MCL-PHA films to determine
their wettability. Distilled water and cell media (200 μL) were
placed on the surface of the film sample using a gas tight syringe.
Ten images of the water/media droplets dispersing on the surface of
the film sample were captured within a frame interval of 1 s. The
analyses of the images were performed using the KSV Cam software.
All work was completed at the Eastman Dental Institute, University
College, London.
Cardiac Progenitor SCs
Isolation of CPCs, Labeling, and Scaffold Seeding
Cell Isolation
CPCs were isolated from adult, C57BL/6,
mouse atria. Specifically, after hearts were excised, they were washed
and digested with 0.05% trypsin–EDTA, and the tissue explants
were plated on fibronectin-coated Petri dishes. They were expanded
in culture as collagenase and trypsin digestion cells (CT) in accordance
to standard methods described previously.[42]
Labeling
Cells were then plated
in Iscove’s modified Dulbecco’s medium (IMDM, Thermo
Fisher Scientific, UK) and incubated in culture with perfluoro-crown-ether
(PFCE)-containing fluorescent nanoparticles (NPs) (containing Atto647)
(10 mg/mL in 1 million cells)[43] and FuGENEHD (Promega, Madison, WI, USA) for approximately 24 h before
trypsinization, isolation, and pelleting. Final cell pellet suspensions
containing approximately 1 million cells each were maintained in cell
media solutions and transferred to Eppendorf volumes containing 1.7
mL IMDM. Labeled cells were used to seed the scaffolds for SEM, MRI/MRS,
and confocal microscopy experiments.
Cell
Seeding
Cells (unlabeled or labeled) were seeded on scaffolds
overnight after isolation and pelleting. The seeding density was 20k/scaffold
for confocal-epifluorescence imaging and 300–500k/scaffold
for in vitro MRI studies, with scaffolds cut at sizes spanning 2–8
× 2–8 mm2. Scaffolds were subsequently washed
with PBS, and fixed cells were seeded [in 2% paraformaldehyde (PFA)/PBS
solution (1:7 v/v)], while live cells were seeded in IMDM media. Scaffolds
were subsequently prepared for high-content, confocal imaging, SEM
or for MRS.In vivo scaffolds were cut into a trapezoidal shape
(the smaller side was implanted toward the apex) with a size of 2
× 5 mm2, with a height of 4 mm. The optimal seeding
density was found to be 300–350k cells in 100 μm porous
scaffolds (the ratio of the final number of cells to the number of
the originally seeded cells was ∼0.6). This estimate was based
on in vitro experiments where Trypan blue cell counts were conducted
upon initial seeding/incubation and on corresponding counts of the
freely floating cells in the IMDM media after the incubation period
followed by the transfer of the scaffold in a new Eppendorf tube with
fresh media. To maximize the cell density, a double-layered scaffold
was implanted in a second mouse and studied in vivo, as reported below.
The double-layered scaffold was composed of two single layer scaffolds
that were glued at their four corners using surgical glue (Histoacryl,
Braun Surgical S.A., Spain).
In Vitro
Cell Adhesion and Proliferation Studies of Seeded Scaffolds
High-Content Microscopy-Epifluorescence Imaging
Epifluorescence Imaging
Live cells were stained with
Calcein (CellTrace Calcein Red-Orange, ThermoFisher Scientific, UK)
for high-content imaging and plated in 96-well plates. Cells (n = 3, ∼20–50k cells/well) were maintained
in culture up to 7 days (D), and a time course study (D1–D7)
of live cells was conducted to assess cell survival (calcein) using
a high-content imaging system (Operetta, Perkin-Elmer, UK) (results
not shown).
Label Detection—Confocal
Microscopy
Fluorescent NPs were imaged [excitation wavelengths:
λgreen = 488 nm, λred = 633 nm,
emission ranges: 500–550 nm (green) and 650–700 nm (red)]
using phase contrast and red/green excitations in control cell samples
and in samples with and without FuGENE, using a Leica TCS SP8 confocal
microscope (Leica-Microsystems, Mainhem, UK) with HyD detectors and
an objective with numerical aperture = 1.4, 63×.
In Vitro, Postmortem, and in Vivo MRI/MRS
Animal Ethics
All experimental procedures involving
animals were approved by the Home Office (UK) and were in accordance
to the guidelines under The Animals (Scientific Procedures) Act, 1986,
the European Animal Research Directive 2010/63/EU, and with local
institutional guidelines.
Radiofrequency Coils
For MRI studies, a 4 × 4 cm2 single-turn, transmit/receive
butterfly coil (implemented on a 28 mm diameter plastic former) [in
vitro/postmortem/in vivo studies] and a 5 (diameter) × 8 (length)
mm2 solenoid coil [in vitro studies] were fabricated in-house
using flexible copper laminate sheaths, tuned, and matched to the 19F resonant frequency at 375.8 MHz. The broad frequency response
of the coil allowed intermittent imaging on the 1H and 19F nuclei.
MRI/MRS of Nonporous
and Porous Scaffolds
In Vitro Studies
Unseeded and seeded scaffolds were maintained in IMDM media and
placed in 0.2–0.7 mL Eppendorf tubes. 1H and 19F MRI/MRS were then conducted. For postmortem studies, 1H/19F MRI measurements were performed on hearts
with control (unseeded) and labeled (seeded) scaffolds positioned
using fibrin glue (Baxter, UK) on the anterior epicardial surfaces.
In Vivo Studies
Healthy mice were anesthetized
and maintained using 1.5% isoflurane. They were then intubated and
underwent a lateral thoracotomy. Scaffolds were positioned on the
anterior myocardium using histoacryl surgical glue (B. Braun Surgical
S.A., Spain). Mice were recovered, monitored for adequate postsurgical
recovery, and transferred to MRI for imaging. They were then re-anesthetized
in accordance to standard imaging protocols. Imaging parameters for
all MRI/MRS acquisitions are listed below.(a) In vitro studies 1H MRI (unseeded/seeded scaffolds): 1H MRI was completed
with two-dimensional (2D) segmented k-space, double-gated
spoiled gradient echo (SPGR), and three-dimensional (3D) ungated sequences.(b) 19F-MRI/MRS: Work was performed on a 9.4 T Varian
scanner. 19F spectra were acquired using nonlocalized acquisitions
(ungated and gated for in vivo scans) with the following parameters:
repetition time (TR) = 800–1000
ms, number of excitations (NEX) = 64 or 256, 512 points, bandwidth
(BW) = 20 kHz, and receiver gain (RG) = 30.(c) In vitro studies 19F MRI (unseeded/seeded scaffolds): Correspondingly, the 19F MRI acquisitions [SPGR, steady state free precession (SSFP)]
were TR = 8.3 ms, TE = 4.17 ms, flip angle = 50°, NEX = 1024,
matrix = 32 × 32, ST = 10 and 40 mm, BW = 4 kHz, RG = 30, and
total acquisition time = 4.3 min.(d) Postmortem studies (unseeded/seeded
and labeled scaffolds): The 2D 1H MRI acquisition parameters
were TR = 2.73 or 3.13 ms, TE = 1.58 ms, flip angle = 50°, NEX
= 32, matrix = 128 × 128, FOV = 40 × 40 mm2,
ST = 1 mm, BW = 100 kHz, and pulse width (pw) = 1500 μs (total
acquisition time = 12.8 s). The 3D 1H MRI acquisition parameters
were TR = 2.63 ms or 2.73 ms, TE = 1.33 or 1.38 ms, flip angle = 20°,
NEX = 4, matrix = 128 × 128 × 128, FOV = 40 × 40 ×
40 mm3, BW = 100 kHz, and total acquisition time = 2.5
min.The corresponding 19F acquisition parameters
were TR = 8.31 ms, TE = 4.17 ms, flip angle = 50°, NEX = 796,
matrix = 32 × 32, ST = 5 mm, BW = 4 kHz, and total acquisition
time = 3.31 min. 19F MRS was acquired with nonselective
excitation using TR = 800 ms, NEX = 256, 512 points, BW = 20 kHz,
and RG = 30.(e) In vivo murine studies: 3D ungated scans were
acquired using the following imaging parameters: TR = 3 ms, TE = 1.68
ms, flip angle = 30°, NEX = 4, matrix = 128 × 128 ×
128, FOV = 40 × 40 × 40 mm2, BW = 100 kHz, and
total acquisition time = 5 min.
Histology
Cellular Retention
Postmortem histological evaluation
was performed at D1 and D7 postscaffold implantation to assess CPC
retention. Mice were euthanized by cervical dislocation under general
anesthesia and the hearts excised. The hearts were then dehydrated
and fixed (either in a 15% sucrose, 0.4% PFA solution, or in a 4%
PFA solution) after which they were embedded in paraffin and stored
(at −80 °C or room temperature). Serial transverse paraffin
sections of 10–17 μm were cut, from base to apex for
histological staining using a nuclear stain 4′,6-diamidino-2-phenylindole
(DAPI). Imaging and analyses were performed on a bright-field optical
and on a confocal microscope [nuclear (DAPI), label (Atto647)].
Image Processing
Image
and Spectral Analyses
Low-resolution 19F MR images
were imported and interpolated in ImageJ (NIH, Bethesda, USA) using
bicubic splines to match the 1H matrix size. Thoracic muscle 1H and 19F MRI were overlaid in ImageJ (opacity
= 40–70%). In vitro and in vivo spectra were read and processed
in CSX (P. Barker-Kennedy Krieger Institute, Johns Hopkins USA) and
using the interactive data language software (IDL, Harris Geospatial,
USA). Signal and signal-to-noise (SNR) ratio values were estimated
using standard methodologies.[44]High-field
polymer spectral processing was conducted using the Mnova software
package (v12, Mestrelab Research, S.L., A Coruna, Spain). The chemical
shifts were referenced against the residual solvent signals at 7.26
and 77.0 ppm for the 1H and 13C spectra, respectively.
Statistical Analyses
All results
are reported as mean ± standard deviation (SD). Paired and unpaired,
two-tailed Student’s t-tests, were also used
(XLSTAT, Addinsoft, New York) for mean comparisons (α = 5%).
Results
Production of PHAs and
Physical Characterization
The polymer was produced by the
fermentation of P. mendocina CH50,
purified, and structurally characterized, as previously described[36] (Figure ). The concentration of the obtained biomass at the end of
fermentation was 1.5 g/L. The final PHA concentration was 0.52 g/L.
Figure 1
Synthetic
and chemical characteristics of polymer: (A) general chemical structure
of polyhydroxyalkanoates (x = 1, 2, 3; n = 100–30 000; R1, R2 = alkyl
groups; C1–C13 units). (B–E) NMR
spectra of the MCL-PHA and MCL-PHA/PCL blend. (F,G) Corresponding
FTIR spectra for MCL-PHA and MCL-PHA/PCL blend depicting the ester
carbonyl bond and C–O stretching peaks. Only the characteristic
peaks for PHAs and PCL are annotated in FTIR spectra.[45,46]
Synthetic
and chemical characteristics of polymer: (A) general chemical structure
of polyhydroxyalkanoates (x = 1, 2, 3; n = 100–30 000; R1, R2 = alkyl
groups; C1–C13 units). (B–E) NMR
spectra of the MCL-PHA and MCL-PHA/PCL blend. (F,G) Corresponding
FTIR spectra for MCL-PHA and MCL-PHA/PCL blend depicting the ester
carbonyl bond and C–O stretching peaks. Only the characteristic
peaks for PHAs and PCL are annotated in FTIR spectra.[45,46]
FTIR and NMR
The polymer was identified to be MCL-PHA using FTIR. The two characteristic
peaks of MCL-PHAs (1726.2 cm–1, indicative of the
ester carbonyl bond, and 1160.0 cm–1, indicative
of C–O stretching) were present in the elicited FTIR spectrum.
Final confirmation of the polymeric structure was carried out using 13C and 1H NMR spectroscopy (Figure and Table ). The observed 1H NMR peak area ratios
for the MCL-PHA were 2:1:2:8:3 (a/b/c/d, d*/e, e*), which exactly
corresponded to the expected ratios from the structure, as shown in Figure B. The elicited ratio
value of 8 obtained for the 1Hs (annotated as d, d*) is
the average of 6 and 10, that is, the number of protons in each monomeric
unit type. In the case of the MCL-PHA/PCL blend, the polymeric peak
ratios matched those of the pure MCL-PHA polymer. Hence, the MCL-PHA
related peak area ratios were 2:1:2:8:3 (a/b/c/d, d*/e, e*), while
those for the PCL were 1:2:1:1 (^a/^b/^c/^d),
as shown in Figure C.
Table 1
Chemical Shifts (δ) for (A) 1H NMR
Peaks and Corresponding Chemical Shifts for (B) 13C Peaks
for MCL-PHA and Caprolactone[37,47]
(A)
proton atoms
3-hydroxyoctanoate (δ, ppm)
caprolactone (δ, ppm)
CH
5.20 (b, multiplet)
4.1 (^a, triplet adjacent to carbonyl group)
CH2
2.50 (a, eightfold
peak)
2.30 (^d, triplet)
CH2
1.58 (c, multiplet)
1.65 (^b, eightfold peak)
other CH2
1.25 (d,
d*, multiplet)
1.40
(^c, multiplet)
CH3
0.88 (e, e*, triplet)
Thermal Properties
DSC was used to determine the thermal
properties of the synthesized materials (Table ). All thermograms showed the presence of
two or more peaks corresponding to the melting and glass transition
temperatures. Tg values for the MCL-PHA
scaffolds (nonporous [n = 4] and porous (75 [n = 1]/100 μm [n = 4]) at 100%) were
−44.5/–44.0/–44.5 °C, while the corresponding
values for the MCL-PHA/PCL blends (with PCL at 95/5%) were −48.2
(n = 4)/–44.2 (n = 1)/–46.5
°C (n = 3). The corresponding Tm values were 52.1 (n = 4)/53.2 (n = 1)/53.6 °C (n = 4) (100% composition)
and 50.4 and 58.3/52.8 and 56.0/51.9 and 59.4 °C for the PCL
blends. Two values are reported for the blends corresponding to the
two distinct peaks elicited in the PCL blend thermograms.
Table 2
Summary of Thermal Characterization Results of Synthesized
Scaffolds
sample
glass transition temperature (°C)
melting temperature
(°C)
MCL-PHA (100%) nonporous [n = 4]
–44.5 ± 1.6
52.1 ± 0.4
MCL-PHA/PCL (95/5%) nonporous [n = 4]
–48.2 ± 0.5
50.4 ± 0.1/58.3 ± 0.1a
MCL-PHA (100%) porous (100 μm) [n = 4]
–44.5 ± 1.9
53.6 ± 0.4
MCL-PHA/PCL (95/5%) porous (100 μm) [n = 3]
–46.5 ± 1.1
51.9 ± 0.1/59.4 ± 0.3a
Reported values correspond to the separate peaks
of the MCL-PHA/PCL thermograms.
Reported values correspond to the separate peaks
of the MCL-PHA/PCL thermograms.
Mechanical Properties
2D patches [nonporous
and porous (75 and 100 μm porosity)] were fabricated using the
solvent casting technique. Controlled porosity is a critical morphological
characteristic for biocompatible scaffolds for cell adhesion and growth.
Therefore, porous patches were fabricated. The porosity was optimized
based on the mechanical properties of the synthesized scaffolds (75,
100 μm), using tensile testing (Figure , Table ).
Figure 2
Mechanical characteristics of synthesized scaffolds: histogram
plots of (A) ultimate tensile strength (MPa), (B) elongation at break
(%), and (C) Young’s modulus (MPa) for the nonporous (n = 4), porous (75 μm [n = 3], and
100 μm [n = 7]) scaffolds. Results represent
mean ± SD values over 3–7 independent tests (Table ).
Table 3
Summary of Mechanical Properties of
the Synthesized Scaffolds
sample
tensile strength (MPa)
elongation
at break (%)
Young’s modulus (MPa)
MCL-PHA (100%) nonporous
7.83
507.25
4.63
MCL-PHA/PCL (95/5%) nonporous
7.40
526.50
4.65
MCL-PHA (100%) porous (75 μm)
2.38
528.00
0.68
MCL-PHA (100%) porous (100 μm)
1.31
212.50
1.92
MCL-PHA/PCL (95/5%) porous (75 μm)
2.34
604.33
0.72
MCL-PHA/PCL (95/5%) porous (100 μm)
0.91
206.00
1.46
Mechanical characteristics of synthesized scaffolds: histogram
plots of (A) ultimate tensile strength (MPa), (B) elongation at break
(%), and (C) Young’s modulus (MPa) for the nonporous (n = 4), porous (75 μm [n = 3], and
100 μm [n = 7]) scaffolds. Results represent
mean ± SD values over 3–7 independent tests (Table ).
Surface Characterization
The surface characteristics of the neat and porous scaffolds were
quantified in terms of wettability and imaged using SEM. Surface morphology
and microstructural features of the optimized porous scaffolds were
visualized in cases of seeded scaffolds with CPCs using SEM, as shown
in Figure .
Figure 3
Surface morphology
of porous scaffolds: morphological characterization of the synthesized
(A,D) porous (MCL-PHA, MCL-PHA/PCL) scaffolds [(A,C) nonseeded, and
(B,D) seeded with cardiac progenitor CT green fluorescent protein
negative cells] using SEM. Indicative results are shown from the
75 μm porous scaffolds.
Surface morphology
of porous scaffolds: morphological characterization of the synthesized
(A,D) porous (MCL-PHA, MCL-PHA/PCL) scaffolds [(A,C) nonseeded, and
(B,D) seeded with cardiac progenitor CT green fluorescent protein
negative cells] using SEM. Indicative results are shown from the
75 μm porous scaffolds.Surface wettability was quantified only for the neat scaffolds
using water and IMDM media with a drop shape analyzer. The mean water
contact angles for the nonporous scaffolds (MCL-PHA vs MCL-PHA/PCL)
were 90.0 ± 11.6°/80.7 ± 4.2° (water) and 88.8
± 6.7°/72.0 ± 2.5° (IMDM), as shown in Figure . The contact angles
were significantly higher in the H2O versus the IMDM cases
(MCL-PHA: p < 0.013, PCL: p <
0.015). Significantly decreased mean contact angles were also observed
in the MCL-PHA/PCL vs MCL-PHA samples in the case of IMDM tests (p < 0.004), indicative of increased hydrophilicity.
Figure 4
Contact
angle measurements in the synthesized scaffolds: mean contact angles
(mean ± SD) over 6–11 independent measurements for three
different samples of each of the synthesized scaffolds (neat MCL-PHA
and MCL-PHA/PCL blend at a composition of 95/5 wt %) using water and
IMDM media.
Contact
angle measurements in the synthesized scaffolds: mean contact angles
(mean ± SD) over 6–11 independent measurements for three
different samples of each of the synthesized scaffolds (neat MCL-PHA
and MCL-PHA/PCL blend at a composition of 95/5 wt %) using water and
IMDM media.
Cardiomyocyte
Cytocompatibility Studies
CPC Cell Density
The biocompatibility, cell surface adherence characteristics, and
cell seeding density of the optimal porous scaffolds (with a porosity
of 100 μm) were assessed using high-content epifluorescent imaging
in vitro, using unlabeled and 19F FuGENE-labeled cells
(50–70k). The first set of experimental tests assessed the
differences of cell adherences on the two types of the porous scaffolds
having an optimal porosity of 100 μm. Elicited results are summarized
in Figure A,B. Figure clearly shows the
increased cell adherence (and correspondingly increased viable cell
density) in the MCL-PHA/PCL (Figure B) compared to the MCL-PHA neat scaffold (Figure B). Quantification
of the total number of viable cells was challenging, given the 3D
porous structure of the scaffold, and its optical scattering characteristics.
Figure 5
Comparison
of in vitro CPC attachment on the two types of synthesized scaffolds:
high-content (epifluorescent) imaging of porous MCL-PHA scaffolds
(with a 100 μm porosity) seeded with (A) unlabeled (∼50–70k
cells) and CT cells [cytoplasmic Calcein stain (orange), nuclear Hoechst
stain (blue)]. Results indicate the lower affinity of porous MCL-PHA
scaffolds for unlabeled cardiac progenitor SCs. (B) Increased cell
density is observed for the porous MCL-PHA/PCL scaffold.
Comparison
of in vitro CPC attachment on the two types of synthesized scaffolds:
high-content (epifluorescent) imaging of porous MCL-PHA scaffolds
(with a 100 μm porosity) seeded with (A) unlabeled (∼50–70k
cells) and CT cells [cytoplasmic Calcein stain (orange), nuclear Hoechst
stain (blue)]. Results indicate the lower affinity of porous MCL-PHA
scaffolds for unlabeled cardiac progenitor SCs. (B) Increased cell
density is observed for the porous MCL-PHA/PCL scaffold.
Noninvasive, Temporal Monitoring
of Scaffolds Using 19F MRS/MRI
In
Vitro, Postmortem, and in Vivo Scaffold Characterization
Of increased interest are the MRS/MRI results from in vitro tests
of the scaffold with optimal porosity (100 μm), summarized in Figures and 7, over a temporal period of 9 days (D1–D9) following
seeding with FUGENE-labeled cells. Constancy of cell retention is
justified in Figure by the 25% integrated MRS area difference between D1 and D3. The
cell density decreased to 44% at D6 and to 30% at D9. MRI also achieved
visualization and clear delineation of the scaffolds using both 1H and 19F MRI, as indicated in Figure . Indicative is the decreased
signal (and SNR) responses at D6 compared to earlier days (Figure G–I).
Figure 6
Temporal, in
vitro MRS characterization of persistence of CPC attachment on the
optimal type of porous scaffolds: magnetic resonance 19F spectra (MRS) of MCL-PHA/PCL (100 μm, 95/5%) scaffolds that
were initially seeded with using 300k FuGENE-labeled CT cells each
at (A–D) days 1 (D1), D3, D6, and D9.
Figure 7
In vitro MR visualization and temporal monitoring of CPC seeded porous
scaffolds: (A–C) indicative axial (A) and coronal/sagittal
(B,C) axis 1H MRI views of a 75 μm porous MCL-PHA/PCL
95/5 wt % blend scaffold (arrows) showing in vitro detectability (samples
immersed in IMDM media in 0.7 mL Eppendorf tubes). (D–F) Corresponding
axis and coronal/sagittal views of a 100 μm porous scaffold
in vitro. (G,I) 19F MRI of seeded scaffold (MCL-PHA/PCL
95/5 wt % blend) with labeled cells. Axial views have a slice thickness
of (G–I) 10 mm at D1, D3, and D6.
Temporal, in
vitro MRS characterization of persistence of CPC attachment on the
optimal type of porous scaffolds: magnetic resonance 19F spectra (MRS) of MCL-PHA/PCL (100 μm, 95/5%) scaffolds that
were initially seeded with using 300k FuGENE-labeled CT cells each
at (A–D) days 1 (D1), D3, D6, and D9.In vitro MR visualization and temporal monitoring of CPC seeded porous
scaffolds: (A–C) indicative axial (A) and coronal/sagittal
(B,C) axis 1H MRI views of a 75 μm porous MCL-PHA/PCL
95/5 wt % blend scaffold (arrows) showing in vitro detectability (samples
immersed in IMDM media in 0.7 mL Eppendorf tubes). (D–F) Corresponding
axis and coronal/sagittal views of a 100 μm porous scaffold
in vitro. (G,I) 19F MRI of seeded scaffold (MCL-PHA/PCL
95/5 wt % blend) with labeled cells. Axial views have a slice thickness
of (G–I) 10 mm at D1, D3, and D6.The seeded scaffolds were successfully tested in the postmortem
mouse using both 19F MRS/MRI, as shown in Figure A–D. Results indicate
responses at the first day following scaffold implantation. More interesting
are the elicited results from the in vivo tests conducted in two C57BL/6
mice, indicating the ability of 19F MRS to detect and track
the labeled, seeded cells, within a week following initial implantation
(Figure E–H).
The two peaks on the left-most part of the PFCE-NPs represent the
accumulated isoflurane peaks, as reported earlier.[48] The double-layered scaffold was also clearly and distinctly
identified in 1H MRI at D1 and D7 (the detected 19F area doubled compared to the single-layered scaffold), as shown
in Figure G,H. The
single-layered scaffold was not visible using 19F MRI as
a result of the low seeding density (<300k at D1) [ultimately dependent
on the scaffold’s size in the case of the mouse] and the heterogeneous
distribution of seeded cells within the scaffold, an effect that worsens
owing to the rhythmic and cyclical contraction–relaxation pattern
of the mouse heart at rates exceeding 350 beats per minute.
Figure 8
In vivo MR
visualization and monitoring of signal responses from CPC seeded scaffolds:
in vivo 1H MRI of seeded scaffolds (with labeled CT cells)
on the antero-lateral murine myocardium of normal C57BL/6 mice at
day 1 (D1) from (A) single-layered and (B) double-layered porous MCL-PHA/PCL
95.5 wt % (100 μm) scaffolds seeded with FuGENE-labeled CT cells.
(C) In vitro axial 19F MRI of the single-layered scaffold.
(D) In vitro comparison of single- and double-layered scaffolds using 19F MRS, and (E–H) corresponding ungated 19F MRS from the in vivo mouse (E,F) (single-layered scaffold), and
(G,H) double-layered scaffold at D1 and D7. (I,J) Two separate axial
views of the fused 1H–19F MRI of the
double-layered scaffold at D1 and D7.
In vivo MR
visualization and monitoring of signal responses from CPC seeded scaffolds:
in vivo 1H MRI of seeded scaffolds (with labeled CT cells)
on the antero-lateral murine myocardium of normal C57BL/6 mice at
day 1 (D1) from (A) single-layered and (B) double-layered porous MCL-PHA/PCL
95.5 wt % (100 μm) scaffolds seeded with FuGENE-labeled CT cells.
(C) In vitro axial 19F MRI of the single-layered scaffold.
(D) In vitro comparison of single- and double-layered scaffolds using 19F MRS, and (E–H) corresponding ungated 19F MRS from the in vivo mouse (E,F) (single-layered scaffold), and
(G,H) double-layered scaffold at D1 and D7. (I,J) Two separate axial
views of the fused 1H–19F MRI of the
double-layered scaffold at D1 and D7.
Histological Characterization of Implanted
Scaffolds
Figure shows a histological short-axis, mid-apical view of the postmortem
heart indicating the sites of cellular migration and retention of
CPCs within the myocardium and the scaffold. Also shown are the existing
cellular entities at the interface of the scaffold and myocardium,
as identified using bright field and confocal imaging (Atto647, DAPI).
Figure 9
Histological
assessment of single- and double-layered porous scaffolds seeded with
CPCs: (A) histological short-axis, mid-apical view of a fixed heart
indicating the sites of scaffold (single layer) attachment, seeded
scaffold cells, and cell retention of CPCs in the neighboring myocardium.
(B–D) Arrows in the middle and right sides of the subfigures
indicate the locations of the scaffold and the scaffold–myocardial
interface. (E–G) Black arrows indicate the locations of detected
cells (CPCs and red blood cells). (H–P) Fluorescent views [nuclear
(DAPI), and label (Atto) presented in grayscale, and fused shown in
color (Atto-red, DAPI-blue)], indicating CPC retention (H, K, N) within
the scaffold and myocardium (white arrows). (Q–V) Corresponding
histological and fluorescent views of the double-layered scaffold
(shown in grayscale). Indicative is the increased number of cells
within the myocardium compared to the single-layered case. Bright
field images have been pseudocolored in different instances for better
visualization.
Histological
assessment of single- and double-layered porous scaffolds seeded with
CPCs: (A) histological short-axis, mid-apical view of a fixed heart
indicating the sites of scaffold (single layer) attachment, seeded
scaffold cells, and cell retention of CPCs in the neighboring myocardium.
(B–D) Arrows in the middle and right sides of the subfigures
indicate the locations of the scaffold and the scaffold–myocardial
interface. (E–G) Black arrows indicate the locations of detected
cells (CPCs and red blood cells). (H–P) Fluorescent views [nuclear
(DAPI), and label (Atto) presented in grayscale, and fused shown in
color (Atto-red, DAPI-blue)], indicating CPC retention (H, K, N) within
the scaffold and myocardium (white arrows). (Q–V) Corresponding
histological and fluorescent views of the double-layered scaffold
(shown in grayscale). Indicative is the increased number of cells
within the myocardium compared to the single-layered case. Bright
field images have been pseudocolored in different instances for better
visualization.
Discussion
In this work, a novel, polymeric MCL-PHA/PCL blend material has
been proposed for use as the substrate of a controlled delivery patch/scaffold
for controlled SC release in cardiac tissue applications.[16,36] Both MCL-PHA and MCL-PHA/PCL polymer types have been studied previously
and have shown exceptional attributes to adhesion and cell proliferation
for SCs.[16,18,24] In particular,
MCL-PHAs have exhibited increased elastomeric responses, low crystallinity,
low tensile strength, low melting points, and high elongations at
break and have been extensively studied in various applications to-date.[49−51] However, blend MCL-PHA/PCL compositions have not been explored previously
for their suitability and responses in applications in vivo or for
temporal imaging with CPCs. We show improved properties from synthesized
scaffolds, capitalizing on the merits of each material class, as discussed
below.
Chemical, Thermal, and Morphological Characteristics
The signaling interplay between the seeded CPCs on scaffolds and
the local microenvironment has been shown to be deterministic for
the cell fate, including migration, proliferation, differentiation,
apoptosis, and/or homing/engraftment.[6] Correspondingly,
the physical, morphological, and functional characteristics are deterministic
for such responses.Furthermore, the biocompatibility and degradability
are essential to silence inflammatory/infectious responses, especially
in cardiac diseases. The scaffold’s long-term stress/strain
and thermoplastic responses are also critical in view of the cardiac
cyclic activity.DSC was used to assess the polymer’s
thermal properties, yielding (as previously shown) two distinct peaks
corresponding to the Tg and Tm values observed within the ranges of 44–47 and
51–56 °C, respectively. Low glass transition and melting
temperatures have a direct elastomeric impact on the material’s
response and are typical for MCL-PHA. Nevertheless, similar thermal
properties were elicited for MCL-PHA and MCL-PHA/PCL blends that are
most suitable for the proposed in vivo scaffold applications.Porosity is also invariably linked with seeding density and the ability
of cells to infiltrate/cross-link, migrate, and for cell ingrowth
(through maximization of the surface area and active binding sites).
Despite pore size disparity, all samples (neat and blends at 95/5%
compositions) were similar in pore and cellular morphology, thus confirming
batch reproducibility.A pore size of 100 μm was chosen,
which is larger than the sizes of cells contained in the heterogeneous
mixture of CPCs [endothelial, fibroblasts, innate cardiac SCs, spanning
a size range of approximately 10–40 μm (mean pore size
(±SD) = 19.5 ± 8.8 μm)] in each spatial dimension.
The porogen concentration used was optimal, in accordance to prior
published work.[17] Smaller pore sizes are
prohibitive for cellular seeding and permeation, whereas large pore
sizes may prove detrimental to the scaffold’s cell retention
capacity.
Mechanical Characteristics
The scaffold’s
rigidity/flexibility is of upmost importance for eliciting proper
functional responses (support for adhesion of seeded cells) and attaining
a proper coupling constant[52] with the injured
myocardium. Correspondingly, the ability to control, study, and quantify
its mechanical characteristics is critical, and these attributes have
been extensively investigated herein.The constitutive law manifested
in terms of the stress–strain response of the material is fully
deterministic for its mechanical response under all operational conditions.
To this effect, stress–strain was quantified for these membranes
at room temperatures. No experimentation was conducted using membrane
samples immersed in buffer solutions, although prior work has shown
additional beneficial effects.[17] The decrease
of the Young’s modulus values for the nonporous versus the
porous counterparts was anticipated. Of importance is the noted decreasing
trend for these values in the case of the blend scaffolds compared
to the MCL-PHA counterparts as reported previously,[53] indicative of a decreased stiffness. The documented disparity
in the trend of Young’s modulus values for scaffolds with targeted
porosities of 75 and 100 μm is attributed to the actual pore
size disparity (from targeted values) and increased pore size variability
in these scaffolds. It is thus likely that the pore distributions
in the two cases at the spatial scale of uniaxial tensile testing
are similar.The elongation at break and tensile strength were
comparable for the neat and porous scaffolds, but significantly smaller
in value compared to PCL constructs,[54] and
significantly higher than the reported ranges for human myocardium
(100–300% for the elongation at break, and 3–15 kPa
for tensile strength).[55,56] The achieved Young’s modulus
values of the optimized (unseeded) porous scaffolds are high compared
to targeted values of murine and human myocardium in the range of
0.02–0.5 MPa.[17,52,54−56] The stiffness of seeded scaffolds is anticipated
to be even higher, exacerbating the scaffold-myocardium stiffness
difference. While such a property is fundamental in achieving an appropriate
mechanical stiffness gradient between the patch and myocardium, the
observed Young’s modulus mismatch is not envisaged to be deleterious
for the proposed applications. We did not anticipate that an exact
match is required for the scaffold to be effective. Instead, we consider
the chemical gradient (owing to the concentration difference of free,
mobile SCs in the scaffold and the endogenous pool of SCs in the innate
myocardium) to be the most critical factor in facilitating an efficient
diffusional-migratory SC process, especially in the case of the injured
myocardium. Reinforcing these arguments is the fact that the stiffness
of MI tissue (as previously characterized using atomic force microscopy[57]) is greater than that of healthy myocardium
(i.e., the stiffness mismatch is smaller). Correspondingly, the chemical
gradient (increased SC density in scaffold vs lack of cells, or minimal
number of recruited SC cells from the endogenous niche pool in MI
tissue) is thus expected to be the predominant driving force for cell
migration.An additional advantage of the scaffold is that it
can act as a passive restraint explant to provide mechanical support
or, equivalently, act as a “passive-assist construct”,
to counteract the induced stress from the myocardial pressure-overload
during remodeling in reperfused MI. The beneficial characteristics
of the scaffold as a possible passive-assist explant are anticipated
to be highly effective in the case of MI, whereby the load restraint
imposed by the attached patch is expected to ameliorate and offset
the dilatatory and hypertrophic response of the injured myocardium,
elicited in the acute (dilation), and chronic MI phases (connective
tissue deposition and scar formation) that ultimately lead to heart
failure. The elongation at break and ultimate tensile strength characteristics
were also within expected operational limits for both healthy and
diseased states.[17,19] Of increased importance are perhaps
the surface characteristics of the scaffold, as described next.The material’s
roughness and hydrophobicity are critical markers relevant to cellular
adhesion and proliferation.[16] The surface
roughness of this MCL-PHA was reported previously based on light interferometric
techniques and measurements[17,19] with a noted increase
in the case of porous versus neat patches.SEM and surface contact
analyses revealed that both the neat and nonporous blend films had
smooth and regular surfaces and that the specific cardiac myocytes
adhered well on the outer surfaces of the nonporous scaffolds.Given that the measured contact angles were 90° or less, both
material types are considered as hydrophilic. As expected, there was
an increased surface hydrophilicity with the use of IMDM, an effect
that is more prominent in the MCL-PHA/PCL blends compared to the MCL-PHA
scaffolds. This is expected as a result of the content of such media
in electrolytes and other proteins that facilitate surface binding
and adhesion. Surface contact angle results (IMDM vs H2O) have also been justified by SEM analyses, indicating good outer
surface adherence of CPCs in both cases (neat and porous). More importantly,
increased hydrophilicity was documented in the case of neat MCL-PHA/PCL
scaffolds compared to their MCL-PHA counterparts, confirmed by the
excellent CPC attachment and increased retention, as shown by confocal
microscopy and 19F MRS findings. Further hydrophilicity
increases are expected from the functionalization of these scaffolds
with VEGF and RGD/YIGSR peptides.[17]
Novel Functional Response in Cardiac Tissue Engineering
Cell Retention, 19F Temporal Persistence, and Noninvasive
Monitoring
The material has been synthesized to attain optimal
characteristics (including pore size, actual physical dimensions,
and biochemical composition) to tailor its physical, chemical, and
thermal characteristics and to optimize the seeding density of CPCs
with fluorinated NPs for visualization and temporal tracking using
MRS over periods spanning >7–9 days.The pore size
of the scaffold has been chosen to be large enough to accommodate
all different types of cells contained in the heterogeneous population
of the seeded CPCs (including primarily innate myocardial, endothelial
cells, and fibroblasts), yet being able to accommodate other types
of cardiac SCs (e.g., mesenchymal, embryonic, inducible-pluripotent,
and others).The scaffold’s seeding density (limited
capacity determined by pore size, thickness, and size of patch ultimately
limited by the murine myocardium) is approximately 350k cells/scaffold,
which is at the limit of the capacity of 19F MRI to detect
and monitor labeled cells using fast imaging with the described imaging
methodologies at 9.4 T.Overall, SC retention has been proven,
yet the cellular attachment can be further improved using VEGF/RGD/YIGSR.
Nevertheless, the ability to maintain cells viable over multiple weeks
is/will continue to be a challenge, as will be the determination on
whether the increased 19F signal observed at later time
periods using the double-layered scaffold is due to released NPs from
lysed cells within the pouch region between the two layers.Temporal-dependent 19F MRI decreases from seeded scaffolds,
likely attributed to cell death, decreased cell adherence, and increased
leaching rates of nonviable and viable cells, need to be investigated
further. Conclusive confirmation is envisaged to be provided by in
vitro dead/live assays and postmortem immunohistochemical assays following
in vivo imaging, as part of future planned work.The engraftment
also needs to be assessed once the optimal scaffold conditions are
attained over periods of 1–8 weeks to assess N-cadherin, connexin,[43] and spatial gap
junction formation and localization within the intercalated disc.[58] Although the exact mechanisms through which
scaffolds exert beneficial effects are still not well understood,
it is likely that they promote neogenesis and angiogenesis in conjunction
with an associated increased SC viability and proliferation, amplifying
the beneficial paracrine effects.Overall, the elicited results
from prior and ongoing clinical trials and preclinical studies of
CPCs and SCs have been promising. Nevertheless, despite the existence
of vast prior work in this field, important questions still remain,
including the optimal choice of cells, growth factors, the scaffold’s
mechanical coupling and directionality of the explants with respect
to the injured myocardium,[58] and the exact
timing of its administration after MI to elicit maximum benefits.[59]
Conclusions
We have presented applicability of MCL-PHA/PCL porous blends fabricated
as thin films with an improved performance compared to MCL-PHAs, capitalizing
on the excellent polymeric properties of natural MCL-PHA polymers,
and the simplified synthetic process relevant to PCLs. We have also
demonstrated superior MCL-PHA/PCL scaffold performance compared to
MCL-PHA scaffolds through experimental comparisons of (a) morphological
data using SEM and (b) contact angle measurements indicative of increased
hydrophilic responses of the blend scaffolds attesting to improved
CPC adhesion, (c) in vitro confocal microscopy showing increased SC
proliferative capacity, (d) mechanical testing that elicited good
overall responses, (e) improved in vitro NMR retention of seeded SCs,
and (f) and in vivo applicability and MRI visualization of labeled
SCs over periods spanning 8 days. The scaffold’s structural
and morphological characteristics are tunable and could allow maximization
of the seeding density for easier detection and temporal follow-up
using direct 19F MRI/MRS in vivo, anticipated to be beneficial
to larger animals/humans. The proposed scaffold can be potentially
modified synthetically to address the induced CPC hypoxic state postscaffold
implantation through the controlled delivery of exogenously administered
oxygen via the scaffold, particularly following MI, as a result of
the loss of perfusion pathways and myocardial vascular obstruction
effects. Additionally, conjugation/functionalization of the scaffold
with angiogenic, vascular growth factors, and peptides, is possible
and is expected to lead to even further increases in cellular attachment
and proliferation, as evidenced previously in MCL-PHA seeded with
other SC types.[17]On the basis of
this work, and the elicited preclinical outcomes in normal mice in
vivo, MCL-PHA/PCL blends are expected to have tremendous potential
as future materials for cardiac patch development. A dual approach
combining direct injections and controlled delivery of CPCs using
these scaffolds is expected to maximize potential benefits following
infarction. For translational purposes, refinement of the synthetic
method of patch production is also envisaged, whereby the automation
of the processing of polymeric synthesis and its direct, in situ injection
can be implemented in accordance to recently published studies.[60,61] Studies on their suitability and effects on MI are ongoing.
Authors: Hidemasa Oh; Steven B Bradfute; Teresa D Gallardo; Teruya Nakamura; Vinciane Gaussin; Yuji Mishina; Jennifer Pocius; Lloyd H Michael; Richard R Behringer; Daniel J Garry; Mark L Entman; Michael D Schneider Journal: Proc Natl Acad Sci U S A Date: 2003-10-06 Impact factor: 11.205
Authors: Lindsay K Hill; Joseph A Frezzo; Priya Katyal; Dung Minh Hoang; Zakia Ben Youss Gironda; Cynthia Xu; Xuan Xie; Erika Delgado-Fukushima; Youssef Z Wadghiri; Jin Kim Montclare Journal: ACS Nano Date: 2019-02-19 Impact factor: 15.881
Authors: Saurav Ranjan Mohapatra; Elena Rama; Christoph Melcher; Tobias Call; Miriam Aischa Al Enezy-Ulbrich; Andrij Pich; Christian Apel; Fabian Kiessling; Stefan Jockenhoevel Journal: Tissue Eng Regen Med Date: 2022-10-06 Impact factor: 4.451
Authors: Carmen J Gil; Martin L Tomov; Andrea S Theus; Alexander Cetnar; Morteza Mahmoudi; Vahid Serpooshan Journal: Micromachines (Basel) Date: 2019-07-16 Impact factor: 2.891
Authors: Francisco G Blanco; Natalia Hernández; Virginia Rivero-Buceta; Beatriz Maestro; Jesús M Sanz; Aránzazu Mato; Ana M Hernández-Arriaga; M Auxiliadora Prieto Journal: Nanomaterials (Basel) Date: 2021-06-04 Impact factor: 5.076
Authors: Qasim A Majid; Annabelle T R Fricker; David A Gregory; Natalia Davidenko; Olivia Hernandez Cruz; Richard J Jabbour; Thomas J Owen; Pooja Basnett; Barbara Lukasiewicz; Molly Stevens; Serena Best; Ruth Cameron; Sanjay Sinha; Sian E Harding; Ipsita Roy Journal: Front Cardiovasc Med Date: 2020-10-23